| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Shelley B Hooks | |
| Jillian H Hurst | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1289-1297 | |
| P577 | publication date | 2009-06-25 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Regulator of G-protein signaling (RGS) proteins in cancer biology | |
| P478 | volume | 78 |
| Q55139050 | A computational framework for complex disease stratification from multiple large-scale datasets. |
| Q36115328 | A finer tuning of G-protein signaling through regulated control of RGS proteins |
| Q33875566 | A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance |
| Q54977082 | Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. |
| Q26796258 | Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer |
| Q30578627 | Chemotaxis in cancer |
| Q33779660 | Comparative genomics uncovers novel structural and functional features of the heterotrimeric GTPase signaling system |
| Q34371923 | DHHC protein-dependent palmitoylation protects regulator of G-protein signaling 4 from proteasome degradation. |
| Q35856860 | Deregulation of RGS17 Expression Promotes Breast Cancer Progression |
| Q38719872 | Development of a bimolecular luminescence complementation assay for RGS: G protein interactions in cells |
| Q33920486 | Development of inhibitors of heterotrimeric Gαi subunits |
| Q47126796 | Discovering cancer vulnerabilities using high-throughput micro-RNA screening |
| Q91944405 | ELMO2 association with Gαi2 regulates pancreatic cancer cell chemotaxis and metastasis |
| Q38720601 | Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells |
| Q35163061 | Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth |
| Q47626622 | Evaluation of the Selectivity and Cysteine Dependence of Inhibitors across the Regulator of G Protein-Signaling Family |
| Q64067047 | Expression and role of regulator of G-protein signaling 5 in squamous cell carcinoma of the tongue |
| Q30176404 | FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex. |
| Q44492106 | FM-GA and CM-GA for Gene Microarray Analysis |
| Q47721663 | Fluorescence polarization assays to measure interactions between Gα subunits of heterotrimeric G proteins and regulatory motifs |
| Q37824814 | G protein-coupled receptors: novel targets for drug discovery in cancer |
| Q37348283 | GPCR ontology: development and application of a G protein-coupled receptor pharmacology knowledge framework |
| Q37731815 | Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer |
| Q34180253 | Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma |
| Q33940693 | Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer |
| Q37815136 | Genetically informed lung cancer medicine |
| Q51532673 | Glutamate E15 and E171 are Hotspots in p60TRP-Related Cancer. |
| Q36734550 | Gαo potentiates estrogen receptor α activity via the ERK signaling pathway |
| Q26801694 | Heterotrimeric G proteins as emerging targets for network based therapy in cancer: End of a long futile campaign striking heads of a Hydra |
| Q89982570 | Heterotrimeric Gq proteins as therapeutic targets? |
| Q37054113 | Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response |
| Q37521291 | Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance |
| Q37714447 | Inhibition of Rgs10 Expression Prevents Immune Cell Infiltration in Bacteria-induced Inflammatory Lesions and Osteoclast-mediated Bone Destruction |
| Q35089640 | Integrating energy calculations with functional assays to decipher the specificity of G protein-RGS protein interactions. |
| Q36405877 | Lymphatic reprogramming by Kaposi sarcoma herpes virus promotes the oncogenic activity of the virus-encoded G-protein-coupled receptor. |
| Q38096149 | Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics |
| Q37537715 | Mx1-cre mediated Rgs12 conditional knockout mice exhibit increased bone mass phenotype. |
| Q36407257 | Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines |
| Q37327676 | Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma. |
| Q47703780 | Proteolytic degradation of regulator of G protein signaling 2 facilitates temporal regulation of Gq/11 signaling and vascular contraction |
| Q30596824 | RGS expression in cancer: oncomining the cancer microarray data |
| Q38756525 | RGS1 expression is associated with poor prognosis in multiple myeloma |
| Q42378395 | RGS19 upregulates Nm23-H1/2 metastasis suppressors by transcriptional activation via the cAMP/PKA/CREB pathway |
| Q38960056 | RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway. |
| Q58583018 | RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia |
| Q47637709 | Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins |
| Q38723931 | Regulator of G Protein Signaling 10 (Rgs10) Expression Is Transcriptionally Silenced in Activated Microglia by Histone Deacetylase Activity |
| Q47435317 | Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway |
| Q37778514 | Regulators of G protein signaling proteins as targets for drug discovery. |
| Q34335443 | Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells |
| Q34198530 | Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets |
| Q27686777 | Regulators of G-protein signaling in the heart and their potential as therapeutic targets |
| Q36756644 | Role of Regulators of G Protein Signaling Proteins in Bone Physiology and Pathophysiology |
| Q39664054 | Role of p115RhoGEF in the regulation of extracellular Ca2+‐induced choline kinase activation and prostate cancer cell proliferation |
| Q37665104 | Role of regulator of G protein signaling proteins in bone. |
| Q57210662 | Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures |
| Q35545728 | Sensitivity and kinetics of signal transmission at the first visual synapse differentially impact visually-guided behavior |
| Q57821602 | Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer |
| Q37526611 | Suppression of GNAI2 message in ovarian cancer |
| Q39352989 | Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment |
| Q30369946 | TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer. |
| Q30397640 | The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR Review 21. |
| Q37279018 | The regulator of G-protein signaling RGS16 promotes insulin secretion and β-cell proliferation in rodent and human islets |
| Q34310119 | Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling. |
| Q34638065 | Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells |
| Q36068725 | miR-181a Targets RGS16 to Promote Chondrosarcoma Growth, Angiogenesis, and Metastasis. |
| Q47103858 | miR-203 inhibits cell proliferation, invasion, and migration of non-small-cell lung cancer by downregulating RGS17. |
Search more.